Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: An open Belgian multicenter study

Significant Increase in High-Density Lipoprotein Cholesterol with Fibrates Is Associated with Low Pretreatment High-Density Lipoprotein Cholesterol: Findings from an Outpatient Clinic Setting

“…Change in HDL-C was significantly associated with pretreatment HDL-C, diabetes, and duration of treatment. Greater increases in HDL-C were observed in patients with lower levels of pretreatment HDL-C, as previously described by Kornitzer et al 16 This pattern was observed independently in both clinics run by the trust.…”

“…15 Increase in HDL-C levels following fibrate treatment has been reported to be maximal in patients with low HDL-C at baseline. 16 Kornitzer et al reported a significant 15.2% mean increase in HDL-C in 1,334 patients after 6 months of treatment with 200 mg of micronized fenofibrate. 16 Patients with baseline HDL-C equal or lower than 0.91 mmol/L (35 mg/dL) demonstrated a larger significant increase of 37.9%.…”

Micronized Fenofibrate in Dyslipidemia

“…Results from the two studies were presented in an abstract and a poster. [35] • • In a subanalysis of the largest of these noncomparative studies, mean HDL-C levels increased by 31.6% among 4711 patients with a baseline HDL-C level of <1.16 mmol/L (p < 0.0001 vs baseline). Average baseline HDL-C values were 1.08 mmol/L [27,34] or 1.32 mmol/L.…”

“…[33] The equivalent-dosage fenofibrate capsule formulation (200 mg/day) also increased HDL-C levels significantly from baseline in patients with various dyslipidemias in large noncomparative studies and maintained the increase for a number of years. [11] Some studies required patients to undergo a 4-week wash-out period, [33] a 3-month low-fat diet and wash-out period [35] or a 2-to 3-month low-fat diet and placebo run-in phase [28] before receiving study treatment. [11] Some studies required patients to undergo a 4-week wash-out period, [33] a 3-month low-fat diet and wash-out period [35] or a 2-to 3-month low-fat diet and placebo run-in phase [28] before receiving study treatment.…”

“…Median absolute increases ranged from 0.13 to 0.16 mmol/L in patients with type IIa or IIb dyslipidemia. [33] • • The capsule formulation (200mg once daily for 12 weeks [27,34] or 6 months [35] ) increased HDL-C levels by 15.2, [35] 17.7 [27] and 22.7% [34] in noncomparative studies (including a German drug monitoring program [34] and a Belgian study [35] ) in 1334, [35] 933 [27] and 7098 [34] patients with various dyslipidemias, respectively (p < 0.0001 vs baseline in two studies; [34,35] the third study did not report any statistical analysis [27] ). Results from the two studies were presented in an abstract and a poster.…”